Patents Examined by Kimberly Aron
-
Patent number: 11407996Abstract: A gene vector for use in gene therapy comprising at least one miRNA sequence target operably linked to a nucleotide sequence having a corresponding miRNA in a hematopoietic progenitor cell (HSPC) or hematopoietic stem cell (HSC) which prevents or reduces expression of the nucleotide sequence in a HSPC or HSC but not in a differentiated cell.Type: GrantFiled: April 15, 2019Date of Patent: August 9, 2022Assignees: Ospedale San Raffaele S.r.l., Fondazione TelethonInventors: Alessandra Biffi, Bernhard Rudolf Gentner, Luigi Naldini
-
Patent number: 11396662Abstract: The present invention provides polynucleotide vectors for high expression of heterologous genes. Some vectors further comprise novel transposons and transposases that further improve expression. Further disclosed are vectors that can be used in a gene transfer system for stably introducing nucleic acids into the DNA of a cell. The gene transfer systems can be used in methods, for example, gene expression, bioprocessing, gene therapy, insertional mutagenesis, or gene discovery.Type: GrantFiled: June 4, 2021Date of Patent: July 26, 2022Assignee: DNA TWOPOINTO INC.Inventors: Jeremy Minshull, Sridhar Govindarajan, Maggie Lee
-
Patent number: 11357870Abstract: The present disclosure provides codon optimized nucleotide sequences encoding human REP1, vectors, and host cells comprising codon optimized REP1 sequences, and methods of treating retinal disorders such as choroideremia comprising administering to the subject a codon optimized sequence encoding human REP1.Type: GrantFiled: August 31, 2021Date of Patent: June 14, 2022Assignee: 4D Molecular Therapeutics Inc.Inventors: David H. Kirn, Melissa A. Kotterman, Peter Francis
-
Patent number: 11326184Abstract: Methods and compositions are provided for making one or more targeted genetic modifications at a target genomic locus within a cell and for producing non-human animals comprising the modified genomic locus. The methods employ two or more large targeting vectors which are capable of recombining with each other and with the target genomic locus in a single genomic targeting step. The methods may also be employed in combination with a nuclease agent. Methods and compositions are also provided for enhancing homologous recombination at a target genomic locus in a cell. The methods employ two or more nucleic acids comprising one or more overlapping sequences. The methods may be employed in combination with a nuclease agent or without a nuclease agent.Type: GrantFiled: December 18, 2015Date of Patent: May 10, 2022Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Vera Voronina, Lynn Macdonald, Brian Zambrowicz, Andrew J. Murphy
-
Patent number: 11318166Abstract: Described herein are methods and compositions using PTH and mesenchymal stem cells (MSCs) for treatment of osteoporosis, bone fractures, and related conditions. Administration of both PTH and MSCs leads to increased homing of MSCs to sites of vertebral bone and rib fracture. The described methods and compositions provide therapeutic approaches that rely, in-part, on stem cell capacity for regeneration and repair. The potential for enhanced bone formation and fracture repair may allow for both preventative and palliative treatments in osteoporotic patients, with combined PTH+MSC therapy producing bone regeneration capacity that is significantly superior to either treatment alone.Type: GrantFiled: June 4, 2015Date of Patent: May 3, 2022Assignee: Cedars-Sinai Medical CenterInventors: Dan Gazit, Edward M. Schwarz, Hyun Bae, Gadi Pelled, Zulma Gazit, Dmitriy Sheyn, Wafa Tawackoli
-
Patent number: 11312936Abstract: The specification describes a composition comprising an improved eukaryotic cell culture medium, which can be used for the production of a protein of interest. Taurine can be added to serum-free media or chemically-defined media to increase the production of a protein of interest. Methods for recombinantly expressing high levels of protein using the media compositions are included.Type: GrantFiled: August 3, 2016Date of Patent: April 26, 2022Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Amy S. Johnson, Meghan E. Casey, Shadia Oshodi, Shawn Lawrence
-
Patent number: 11306291Abstract: The present invention relates to production of proteins in insect cells whereby repeated coding sequences are used in baculoviral vectors. In particular the invention relates to the production of parvoviral vectors that may be used in gene therapy and to improvements in expression of the viral rep proteins that increase the productivity of parvoviral vectors.Type: GrantFiled: December 11, 2018Date of Patent: April 19, 2022Assignee: UNIQURE IP B.V.Inventors: Andrew Christian Bakker, Wilhelmus Theodorus Johannes Maria Christiaan Hermens
-
Patent number: 11297829Abstract: The present invention relates generally to systems and methods for preparing, storing, shipping and using skin equivalents made by organotypic culture. In particular, the present invention relates to systems and methods for cryopreserving viable skin substitutes.Type: GrantFiled: September 5, 2018Date of Patent: April 12, 2022Assignee: Stratatech CorporationInventors: B. Lynn Allen-Hoffmann, John C. Pirnstill, Kenneth R. Gratz, Allen R. Comer
-
Patent number: 11285168Abstract: Tumor growth was found to be significantly suppressed in vivo by inhibiting both miRNA containing 5?-AACACUG-3? as a seed sequence and miRNA containing 5?-AAUACUG-3? as a seed sequence. The inhibition significantly altered the proportion of subpopulations of tumor cells and reduced the tumorigenicity in all subpopulations. The inhibition also exerted a remarkable tumor-shrinking effect on already-formed tumors. The present invention provides novel therapeutic potential against tumor.Type: GrantFiled: September 27, 2016Date of Patent: March 29, 2022Assignee: NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITYInventors: Hideo Iba, Takeshi Haraguchi
-
Patent number: 11279745Abstract: The present invention relates to plasmids useful for prevention and/or delay of e.g. type 1 diabetes.Type: GrantFiled: April 26, 2019Date of Patent: March 22, 2022Assignee: Novo Nordisk A/SInventors: Jay Chaplin, Michael Wijaranakula
-
Patent number: 11253576Abstract: In some aspects, the disclosure relates to compositions and methods useful for the diagnosis and treatment of neurodegenerative diseases, such as leukodystrophies (e.g., Canavan Disease). In some embodiments, the methods comprise administering to a subject an N-acetylaspartate (NAA)-depleting agent or an N-acetylaspartate (NAA)-depleting agent based upon the subject's metabolic profile.Type: GrantFiled: October 21, 2016Date of Patent: February 22, 2022Assignee: University of MassachusettsInventors: Guangping Gao, Dominic Gessler
-
Patent number: 11248209Abstract: This invention provides methods to prepare and use immunostimulatory cells for enhancing an immune response. The invention provides a method for preparing mature dendritic cells (DCs), comprising the sequential steps of: (a) signaling isolated immature dendritic cells (iDCs) with a first signal comprising an interferon gamma receptor (IFN-?R) agonist and/or a tumor necrosis factor alpha receptor (TNF-?R) agonist to produce signaled dendritic cells; and (b) signaling said signaled dendritic cells with a second transient signal comprising an effective amount of a CD40 agonist to produce CCR7+ mature dendritic cells. Also provided by this invention are enriched populations of dendritic cells prepared by the methods of the invention. Such dendritic cells have enhanced immunostimulatory properties and increased IL-12 secretion and/or decreased IL-10 secretion. CD40 signaling can be initiated by one or more of polypeptide translated from an exogenous polynucleotide encoding CD40L (e.g.Type: GrantFiled: December 20, 2016Date of Patent: February 15, 2022Assignee: CoImmune, Inc.Inventors: Don Healey, Irina Tcherepanova, Melissa Adams
-
Patent number: 11234419Abstract: Genetically modified non-human animals and methods and compositions for making and using them are provided, wherein the genetic modification comprises a deletion in an immunoglobulin constant region CH1 gene (optionally a deletion in a hinge region) of an IgG, IgA, IgD, and/or IgE, and wherein the mouse is capable of expressing a functional IgM. Genetically modified mice are described, including mice having a functional IgM gene and modified to have a deletion of a CH1 domain and a hinge region in a heavy chain constant domain that is not an IgM, e.g., in an IgG heavy chain constant domain. Genetically modified mice that make human variable/mouse constant chimeric heavy chain antibodies (antibodies that lack a light chain), fully mouse heavy chain antibodies, or fully human heavy chain antibodies are provided.Type: GrantFiled: March 31, 2015Date of Patent: February 1, 2022Assignee: Regeneran Pharmaceuticals, Inc.Inventors: Lynn Macdonald, Sean Stevens, Andrew J. Murphy
-
Patent number: 11224207Abstract: Genetically modified non-human animals are provided that express an immunoglobulin variable domain that comprises at least one histidine, wherein the at least one histidine is encoded by a substitution of a non-histidine codon in the germline of the animal with a histidine codon, or the insertion of a histidine codon in a germline immunoglobulin nucleic acid sequence. Immunoglobulin genes comprising histidines in one or more CDRs, in an N-terminal region, and/or in a loop 4 region are also provided. Immunoglobulin variable domains comprising one or more histidines (e.g., histidine clusters) substituted for non-antigen-binding non-histidine residues. Non-human animals that are progeny of animals comprising modified heavy chain variable loci (V, D, J segments), modified light chain variable loci (V, J segments), and rearranged germline light chain genes (VJ sequences) are also provided. Non-human animals that make immunoglobulin domains that bind antigens in a pH-sensitive manner are provided.Type: GrantFiled: September 13, 2017Date of Patent: January 18, 2022Assignee: Regeneran Pharmaceuticals, Inc.Inventors: John McWhirter, Lynn Macdonald, Joel H. Martin, Andrew J. Murphy
-
Patent number: 11219644Abstract: Embodiments of the disclosure encompass adoptive immunotherapy related to cells expressing multiple chimeric antigen receptors (CARs). In specific embodiments, T cells express a HER2-specific CAR, an IL13 R?2-specific CAR, and an EphA2-specific CAR. In particular embodiments, the cells are utilized for cancer treatment, including for glioblastoma.Type: GrantFiled: January 26, 2016Date of Patent: January 11, 2022Assignee: Baylor College of MedicineInventors: Nabil M. Ahmed, Kevin Bielamowicz, Kristen Fousek
-
Patent number: 11192949Abstract: A method for inducing an immune response against HIV in a subject includes the step of preparing an HIV-1 gp120 envelope protein coding sequence particle having an N425K mutation, introducing the HIV-1 gp120 protein coding sequence particle having an N425K mutation into an expression construct using yeast homologous recombination, transfecting a cell with the expression construct, wherein the HIV-1 particle is secreted by the cell, and administering the secreted HIV-1 particle and a pharmaceutically acceptable carrier to the subject, wherein the secreted HIV-1 particle stimulates an immune response in the subject.Type: GrantFiled: June 5, 2018Date of Patent: December 7, 2021Assignee: CASE WESTERN RESERVE UNIVERSITYInventors: Eric J. Arts, Annette Burkhouse
-
Patent number: 11180763Abstract: Provided is an SgRNA combination, comprising an SgRNA specifically targeting the GGTA1 gene, an SgRNA specifically targeting the CMAH gene and an SgRNA specifically targeting the ?4GalNT2 gene. Also provided is a CRISPR/Cas9 vector combination, comprising a GGTA1-CRISPR/Cas9 vector, a CMAH-CRISPR/Cas9 vector and a ?4GalNT2-CRISPR/Cas9 vector. Also provided is an applicaton of the CRISPR/Cas9 vector combination in knocking out the GGTA1 gene, the CMAH gene and the ?4GalNT2 gene. The knockout rates of the three genes with the specifically targeted SgRNA sequences are respectively 56%, 63%, and 41%. A three genes knockoutpig can be obtained, wherein the three genes related to immune rejectionare knocked out, and heart valves of said pig can be acquired.Type: GrantFiled: March 14, 2019Date of Patent: November 23, 2021Assignee: Nanjing Genefriend-Biotech Inc.Inventors: Yifan Dai, Haiyuan Yang, Ying Wang
-
Genetically modified pigs for xenotransplantation of vascularized xenografts and derivatives thereof
Patent number: 11179496Abstract: The present invention provides certain donor animals, tissues and cells that are particularly useful for xenotransplantation therapies. In particular, the invention includes porcine animals, as well as tissue and cells derived from these, which lack any expression of functional alpha 1,3 galactosyltransferase (aGT) and express one or more additional transgenes which make these animals suitable donors for xenotransplantation of vascularized xenografts and derivatives thereof. Methods of treatment and using organs, tissues and cells derived from such animals are also provided.Type: GrantFiled: August 13, 2013Date of Patent: November 23, 2021Assignee: Revivicor, Inc.Inventor: David Ayares -
Patent number: 11173186Abstract: A method of treating a human patient comprising systemically administering multiple doses of a parenteral formulation of a replication capable oncolytic adenovirus of subgroup B in a single treatment cycle, wherein the total dose given in each dose is in the range of 1×1010 to 1×1014 viral particles, and wherein each dose of virus is administered over a period of 1 to 90 minutes, for example at a rate of viral particle delivery in the range of 2×1010 particles per minute to 2×1012 particles per minute. Also provided are formulations of the oncolytic adenoviruses and combination therapies of the viruses and formulations with other therapeutic agents.Type: GrantFiled: June 12, 2014Date of Patent: November 16, 2021Assignee: PSIOXUS THERAPEUTICS LIMITEDInventors: John William Beadle, Kerry Fisher, Christine Wilkinson Blanc
-
Patent number: 11154574Abstract: Genetically modified compositions, such as non-viral vectors and tumor infiltrating lymphocytes, for the treatment of gastrointestinal cancer are disclosed. Disclosed are methods of utilizing a CRISPR system to generate genetically modified compositions. Also disclosed are the methods of making and using the genetically modified compositions for the treatment of gastrointestinal cancer.Type: GrantFiled: May 28, 2020Date of Patent: October 26, 2021Assignees: Regents of the University of Minnesota, Intima Bioscience, Inc., The United States of America, as Represented by the Secretary, Department of Health and Human ServicesInventors: Branden Moriarity, Beau Webber, Modassir Choudhry, Steven A. Rosenberg, Douglas C. Palmer, Nicholas P. Restifo